News coverage about Edwards Lifesciences (NYSE:EW) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Edwards Lifesciences earned a news impact score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.1018768430601 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Form 4 Edwards Lifesciences For: May 23 Filed by: BOBO DONALD E JR (streetinsider.com)
- Insider Selling: Edwards Lifesciences (EW) VP Sells 9,815 Shares of Stock (americanbankingnews.com)
- EuroPCR 2018 Roundup: Edwards reportedly pauses Centera valve EU launch (massdevice.com)
- Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report? (zacks.com)
- BRIEF-Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve (reuters.com)
A number of brokerages recently weighed in on EW. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research report on Wednesday. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Monday, May 7th. Cowen reissued a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences in a research report on Thursday, February 1st. Stifel Nicolaus reissued a “buy” rating and issued a $155.00 price target on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Finally, JMP Securities boosted their price target on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, February 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $148.87.
NYSE EW traded down $1.62 during trading on Friday, reaching $135.95. The company’s stock had a trading volume of 1,002,330 shares, compared to its average volume of 1,186,371. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.63 and a current ratio of 2.07. The firm has a market cap of $28.66 billion, a PE ratio of 35.78, a P/E/G ratio of 1.99 and a beta of 0.64. Edwards Lifesciences has a twelve month low of $100.20 and a twelve month high of $143.22.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The business had revenue of $938.00 million for the quarter, compared to analyst estimates of $936.69 million. During the same period in the previous year, the business posted $0.94 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. research analysts predict that Edwards Lifesciences will post 4.63 earnings per share for the current year.
In other news, CFO Scott B. Ullem sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 28th. The shares were sold at an average price of $137.33, for a total transaction of $3,433,250.00. Following the transaction, the chief financial officer now directly owns 35,968 shares in the company, valued at $4,939,485.44. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Jean-Luc M. Lemercier sold 5,633 shares of the business’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $136.29, for a total transaction of $767,721.57. Following the transaction, the vice president now owns 44,298 shares in the company, valued at $6,037,374.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 268,815 shares of company stock worth $36,597,924. Company insiders own 1.84% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.